ASMB vs. NKTR, OMER, CPIX, LLY, JNJ, ABBV, MRK, PFE, BMY, and ZTS
Should you be buying Assembly Biosciences stock or one of its competitors? The main competitors of Assembly Biosciences include Nektar Therapeutics (NKTR), Omeros (OMER), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol Myers Squibb (BMY), and Zoetis (ZTS). These companies are all part of the "pharmaceuticals" industry.
Assembly Biosciences vs. Its Competitors
Assembly Biosciences (NASDAQ:ASMB) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.
Assembly Biosciences has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.
Assembly Biosciences presently has a consensus price target of $33.00, indicating a potential upside of 77.80%. Nektar Therapeutics has a consensus price target of $84.17, indicating a potential upside of 258.61%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Nektar Therapeutics is more favorable than Assembly Biosciences.
19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 5.3% of Assembly Biosciences shares are held by company insiders. Comparatively, 3.7% of Nektar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Assembly Biosciences has higher earnings, but lower revenue than Nektar Therapeutics. Assembly Biosciences is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Nektar Therapeutics had 7 more articles in the media than Assembly Biosciences. MarketBeat recorded 14 mentions for Nektar Therapeutics and 7 mentions for Assembly Biosciences. Nektar Therapeutics' average media sentiment score of 0.40 beat Assembly Biosciences' score of 0.20 indicating that Nektar Therapeutics is being referred to more favorably in the news media.
Assembly Biosciences has a net margin of -124.15% compared to Nektar Therapeutics' net margin of -152.49%. Assembly Biosciences' return on equity of -131.77% beat Nektar Therapeutics' return on equity.
Summary
Nektar Therapeutics beats Assembly Biosciences on 10 of the 17 factors compared between the two stocks.
Get Assembly Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ASMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Assembly Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:ASMB) was last updated on 7/8/2025 by MarketBeat.com Staff
